Avinger, Inc.

50 articles with Avinger, Inc.

• Avinger Announces Key Opinion Leader Presentation and Live Case at Vascular Conferences in Germany

  5/16/2022

  Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany.

• Avinger Reports First Quarter 2022 Results

  5/10/2022

  Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2022.

• Avinger to Announce First Quarter 2022 Results on May 10

  4/29/2022

  Avinger, Inc., announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022.

• Avinger Announces Full Commercial Launch of Lightbox 3

  4/19/2022

  Avinger, Inc. today announced full commercial availability of its new Lightbox 3 imaging console designed to enhance the user experience and drive faster adoption at new hospital sites.

• Avinger Announces Issuance of Three New U.S. Patents in March 2022

  3/30/2022

  Avinger, Inc. today announced the issuance of three new U.S. patents in March 2022 and provided an update on the expansion of its intellectual property portfolio.

• Avinger Regains Compliance with Nasdaq Listing Requirements - Mar 29, 2022

  3/29/2022

  Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced it has regained compliance with Nasdaq listing requirements.

• Avinger Reports Fourth Quarter and Year End 2021 Results

  3/22/2022

  Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the fourth quarter and full year ended December 31, 2021.

• Avinger to Announce Full-Year 2021 Results on March 22

  3/15/2022

  Avinger, Inc. today announced that it will release its financial results for the fourth quarter and full year 2021 after the close of trading on Tuesday, March 22, 2021.

• Avinger to Effect One-for-Twenty Reverse Stock Split

  3/14/2022

  Avinger, Inc. today announced that the Company will effect a 1-for-20 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Monday, March 14, 2022.

• Avinger Expands Lightbox 3 First Case Experience

  3/7/2022

  Avinger, Inc. today announced the expansion of first case experience with its new Lightbox 3 imaging console to four additional hospitals in Pennsylvania and New Jersey.

• Avinger Announces Successful Completion of First Cases with the Lightbox 3 Next Generation Imaging Console

  2/28/2022

  Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced that physicians in the U.S. have successfully completed first cases with its new Lightbox 3 imaging console.

• Avinger Announces Closing of $7.6 Million Registered Direct Offering

  1/14/2022

  Avinger, Inc. announced the closing of its previously announced registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock and warrants to purchase up to an aggregate of 16,150,000 shares of common stock to certain institutional investors for gross proceeds of $7.6 million.

• Avinger Announces $7.6 Million Registered Direct Offering

  1/12/2022

  Avinger, Inc. today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale in a registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock.

• Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console

  1/11/2022

  Avinger, Inc. today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.

• Avinger Announces FDA Clearance of Pantheris for the Treatment of In-Stent Restenosis

  11/17/2021

  Avinger, Inc. today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for a new clinical indication for the Pantheris image-guided atherectomy system.

• Avinger Reports Third Quarter 2021 Financial Results

  11/11/2021

  Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, reported results for the third quarter ended September 30, 2021.

• Avinger to Announce Third Quarter Results on November 11, 2021

  10/29/2021

  Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2021 after the close of trading on Thursday, November 11, 2021.

• Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA

  10/7/2021

  Avinger, Inc. today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA conference in Las Vegas.

• Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

  9/8/2021

  Avinger, Inc. today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

• Avinger OCT-Guided Technologies Featured at AMP 2021

  8/16/2021

  Avinger, Inc. today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week.